Open AccessCD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy
Author(s) -
Qie Guo,
Li Xiao,
Mengna Cui,
J Sun,
Hongyan Ji,
Beibei Ni,
Mei Xing Yan
Publication year - 2020
Publication title -
oncology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 57
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504020x15919605976853
Subject(s) - multiple drug resistance , chemotherapy , cancer , medicine , cancer chemotherapy , cancer cell , drug resistance , oncology , cancer research , intensive care medicine , biology , genetics
Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.